Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05954312 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT05954312: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.
NCT05954312 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Vividion Therapeutics. The registered enrollment target is 290 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05954312, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Vividion Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Primary Outcome
Incidence and severity of DLTs will be assessed per DLT criteria set forth in the protocol based on adverse events (AEs) evaluated per National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG VVD-130037
Study Locations (20)
Other
- National Cancer Center - Goyang
- Gachon University Gil Medical Center - Incheon
- Seoul National University; Bundang Hospital - Seongnam
- Asan Medical Center - Seoul
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital; Yonsei University Health System - Seoul
- The Catholic University of Korea, St. Vincent's Hospital - Suwon
- Hospital Vall d'Hebron - Barcelona
- START Barcelona Hospital HM Nou Delfos - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Ramon y Cajal - Madrid
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Florida Cancer Specialists - Sarasota
- Moffitt Cancer Center - Tampa
Texas
- MDACC - Houston
- NEXT Dallas - Irving
Minnesota
- Mayo Clinic Rochester - Rochester
Tennessee
- Sarah Cannon Research Institute - Nashville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
What NCT05954312 shows while recruiting
NCT05954312 is an interventional study that assigns participants to a tested intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT05954312 names 20 study sites across 6 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05954312 about?
NCT05954312 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors". A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
What is the current status of trial NCT05954312?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2023-07-28. Estimated completion is 2031-02-28.
What conditions does trial NCT05954312 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT05954312?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), VVD-130037 (DRUG).
Who is sponsoring clinical trial NCT05954312?
This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05954312 being conducted?
This trial has 20 study locations across Florida, Minnesota, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05954312's enrollment target sits among peer trials
290 29th of 144 higher than 116 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI